Nymox's NicAlert(TM) Has Achieved Widespread Acceptance in Tobacco-Related Research Studies
March 27 2013 - 11:00AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today that
the Company's FDA Cleared NicAlert™ product continues to achieve
widespread acceptance around the world as an important tool in
tobacco-related research studies and programs in a broad range of
healthcare areas. Researchers in the UK, Canada, Holland,
Switzerland, Australia, Brazil, India, and Hong Kong as well as
those in major research institutions across the U.S. are employing
NicAlert™ in their studies as reported in many new and recent
peer-reviewed publications.
NicAlert™ testing has been used in such areas as:
- studies of the effectiveness of tobacco cessation programs
(e.g. Addictive Behaviors March 2013; 38 1792–1795; Journal of
Perinatology (2012) 32, 374–380; J Am Board Fam Med. 2013
Jan-Feb;26(1):61-70);
- the extent of exposure to secondhand smoke by children of
smokers (Thorax 2013 online publication February 10, 2013);
- the accuracy of NicAlert™ to verify smoking status in patients
about to undergo surgery (Nicotine Tob Res. 2013 Mar 20. [Epub
ahead of print]); and
- the use of saliva NicAlert™ for confirmation of smoking status
by dentists treating periodontal disease (J Indian Soc Periodontol.
2012 Oct-Dec;16(4): 508–512).
NicAlert™ received clearance from the U.S. Food and Drug
Administration to measure tobacco use and exposure and achieved
certification for sale in the European Union with the CE Mark. The
saliva-based version of NicAlert™ has achieved certification with
the CE Mark, permitting its sale in the European Union. TobacAlert™
which employs the same technology is available for non-medical use
as an over-the counter product in the U.S. for detecting
second-hand smoke exposure using urine samples.
"NicAlert™ provides a quick, simple, and inexpensive means for
companies, universities, hospitals and research institutions to
verify smoking status and obtain a semi-quantitative measure of a
person's level of tobacco use or exposure," said Brian Doyle,
Nymox's Director of Business Development. "NicAlert™ testing does
not require special training and can deliver accurate results on
site in a matter of minutes. Now researchers and staff can
screen potential subjects in a matter of minutes rather than having
to wait hours or days for the results to come back from the lab.
This generates efficiency and saves time and expense for all
concerned."
NicAlert™ employs Nymox's proprietary technology to measure
levels of cotinine, a metabolite of nicotine widely accepted to
determine tobacco product use and second-hand smoke exposure. The
product requires no instruments for its use and provides an on-site
visual read-out of the level of tobacco use or exposure within
minutes.
Independent studies have confirmed the accuracy and
effectiveness of Nymox's testing technology. Recently published
independent studies confirming the accuracy of NicAlert™ to verify
smoking status as compared to much more complex and expensive
laboratory testing include Nicotine Tob Res. 2013 Mar 20. [Epub
ahead of print] and Drug Alcohol Depend. 2011; 119: 130–133. An
earlier study by researchers at the Centers for Disease Control and
Prevention (CDC) found that NicAlert™ measurements correlated well
with the far more complex laboratory testing (liquid
chromatography-mass spectrometry) used in the CDC laboratory
(Journal of Analytical Toxicology 2005; 29: 814-818). Other
studies have also found the technology employed in NicAlert™ to be
accurate, rapid and cost-effective (Cancer Epidemiology, Biomarkers
& Prevention 2007; 16:1858-62; Cancer Epidemiology, Biomarkers
& Prevention 2002; 11:1123-1125; Nicotine & Tobacco
Research 2002; 4:305-9).
NicAlert™ comes in two formats: NicAlert™ Saliva which uses
saliva samples for verifying smoking status and measuring high
levels of consumption and NicAlert™ Urine which uses urine samples
and can provide data not only on smoking status but also
second-hand smoke exposure and levels of tobacco product use.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current
expectations. Development of drug products involves
substantial risks and actual results may differ materially from
expectations. Such factors are detailed from time to time in
Nymox's filings with the United States Securities and Exchange
Commission and other regulatory authorities.
CONTACT: For Further Information Contact:
Brian Doyle
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2024 to May 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From May 2023 to May 2024